HD-OPM Archive

Cholesterol myths: 'low cholesterol kills', 'LDL doesn't matter' and more

Why the most common cholesterol-denial claims (low cholesterol is deadly, the body needs high blood cholesterol, LDL is just a marker) do not hold up, and what the genetic, trial and cohort evidence discussed in the group actually shows.

17 min read49 group posts cited38 studies discussed3 chartsEvidence through Oct 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • Low cholesterol in observational data tracks illness, not harm. People born with genetically low LDL have less heart disease, normal cancer rates and normal lifespans.
  • Blood holds only about 2-5% of the body's cholesterol (roughly 3-7 g of 120-150 g); cells and the brain make their own, and the adrenals and gonads need only tens of mg a day from the blood.
  • Across genetics, statins, ezetimibe and PCSK9 inhibitors, risk falls in proportion to how much LDL falls; one cited chart reads about 50-55% lower risk per 1 mmol/L of lifelong lowering.
  • Very low LDL has been tested directly: FOURIER patients reached a median LDL-C of 30 mg/dL with 15% fewer primary events, and levels under 20 mg/dL showed no excess hemorrhagic stroke in a stroke subgroup.
  • Real nuances exist: LDL is necessary but not always sufficient, ApoB can outperform LDL-C, and LDL targets should scale with absolute risk rather than "lower for everyone".
In this summary
  1. Myth 1: "People with low cholesterol die more, so high cholesterol is healthy"
  2. Myth 2: "The body needs cholesterol for hormones and the brain, so keep blood levels high"
  3. Myth 3: "LDL is only a marker, and the research is flawed"
  4. Myth 4: "Very low LDL is dangerous"
  5. Other claims that travel with cholesterol denial
  6. What this means for you
  7. Frequently asked questions
  8. The evidence behind this summary

Several claims circulate widely on social media: that people with low cholesterol die sooner, that the body needs high blood cholesterol for hormones and the brain, and that LDL ("bad") cholesterol is a harmless bystander in heart disease. The group's admins, Louis Nervegna and Gokhan Can, have returned to these claims again and again, and the posts converge on one answer. Each myth starts from something real (a true statistical association, or a true fact about biology) and then draws a conclusion that the evidence does not support.12

This summary goes through the myths one at a time. The short version is that low measured cholesterol in sick people is mostly a consequence of disease; that the cholesterol your cells need is largely made inside the cells, not delivered from the blood; and that when LDL is lowered by genes, by drugs or by diet, cardiovascular risk falls roughly in proportion. The summary also covers where the group itself urges nuance, because "LDL matters" does not mean "lower is always better for everyone".

Some terms first. LDL-C is the cholesterol carried inside low-density lipoprotein particles, as measured on a standard blood test. ApoB (apolipoprotein B) is a protein found on each LDL-type particle, so it counts the particles rather than the cholesterol inside them. Reverse causation means the apparent "cause" is actually a result of the outcome. Mendelian randomization uses naturally occurring gene variants, fixed at conception, as a natural lifelong experiment.

2–5%of the body's cholesterol is in the blood: about 3-7 g of 120-150 g34
52 yearsaverage exposure in Mendelian randomization studies that found no extra cancer with lower cholesterol5
30 mg/dLmedian LDL-C reached in FOURIER, with 15% fewer primary events6
200+cohort, genetic and randomized studies (over 2 million people) showing a dose-dependent LDL effect7

Myth 1: "People with low cholesterol die more, so high cholesterol is healthy"

What the claim gets right

Observational studies do show that lower measured cholesterol is associated with higher mortality in older and sicker populations. A post quoting Barbell Medicine concedes that associations such as higher cholesterol going with less cognitive decline, fewer infections and less cancer are real, but calls the conclusion drawn from them wrong.1

Why the conclusion fails: reverse causation

The explanation the group returns to most is reverse causation. Diseases that kill people in old age, such as cancer, organ failure and slow chronic illness, drive cholesterol down in the months and years before death. If you measure a room of older people once, the ones at the low end are disproportionately already sick, so the low-cholesterol group dies sooner even though cholesterol played no part.1

The Barbell Medicine graphic quoted in the group: the claim draws an arrow from low cholesterol to death, while serious disease actually drives both, lowering cholesterol first.
The Barbell Medicine graphic quoted in the group: the claim draws an arrow from low cholesterol to death, while serious disease actually drives both, lowering cholesterol first.1

Louis points out that the Wikipedia article on "correlation does not imply causation" uses exactly this case as its example: some diseases, such as cancer, lower cholesterol (through weight loss and other factors) and also raise mortality.10 Gokhan makes the same point, calling the link between low LDL-C and mortality a marker of illnesses such as cancer or liver disease rather than a cause.11

The timing test: genes and trials

The decisive evidence is about timing. Some people are born with gene variants that keep LDL low for life, set at conception, long before any diet or illness could influence it. According to the post Louis quoted, these people get less heart disease, have normal cancer risk and live just as long as everyone else. The fact that people with measured low cholesterol show more cancer, while those with genetically low cholesterol do not, tells you that cancer is lowering the cholesterol.1

For cancer specifically, Louis quotes a Circulation review on reverse causality (2017). It reports that serial trial data show cholesterol declining faster before a cancer diagnosis than in people who stay cancer-free, that statin randomized trials show no increase in cancer, and that Mendelian randomization studies, with an average of 52 years of lifetime exposure, show no higher cancer rates in people with lower cholesterol.5

Another shared post rebuts the claim that LDL research is flawed: over 200 prospective cohort, genetic and randomized studies with over 2 million participants, 20 million person-years and 150,000+ cardiovascular events show a dose-dependent relationship between LDL-C and atherosclerotic cardiovascular disease. It adds that illnesses such as cancer, infections and some liver diseases can lower LDL, so low LDL can be a consequence of illness.7

U-shaped curves are common and misleading

Louis stresses that U-shaped mortality curves, where both low and high values look worse, appear for many measurements, not just cholesterol: BMI, A1C and blood pressure too. Few people believe the optimal BMI is 28, the optimal A1C is 6 to 8.5, or the optimal systolic blood pressure is 140 to 150, even though observational charts can suggest it. The consensus explanation, he says, is reverse causality: cancer lowers LDL and BMI, liver or kidney disease lowers A1C, uncontrolled diabetes lowers blood pressure.12 The group repeatedly points members to Nutrition Made Simple videos on this topic, and Louis's summary is that "lowering LDL does not increase mortality".131415

What happens when LDL is actually lowered

Genetics point the other way. A Mendelian randomization study cited in the group estimates that each standard deviation of lifelong lower LDL-C adds about 1.2 years of expected lifespan, proportionally more for larger reductions.16 A separate Mendelian randomization study of 46 modifiable risk factors found that genetically higher LDL and total cholesterol were among nine factors associated with lower odds of reaching age 90 or 99, while higher HDL was associated with greater odds.17

Myth 2: "The body needs cholesterol for hormones and the brain, so keep blood levels high"

The first half is true: cholesterol is essential for life, as a building block of cell membranes and hormones.18 The second half does not follow.

Louis highlights several points from a physiology breakdown by Peter Megdal, PhD:

  • The body holds about 120-150 g of cholesterol, but only about 3-7 g (roughly 2-5%) is in the blood. The rest sits inside cells, mostly in cell membranes.34
  • Most cells make almost all the cholesterol they need internally. Nearly every cell with a nucleus does this, via the mevalonate pathway in which HMG-CoA reductase is the rate-limiting enzyme.419
  • The brain holds about 25% of the body's cholesterol, and none of it comes from the bloodstream, because LDL cannot cross the blood-brain barrier.34
  • The net daily demand on blood cholesterol from the adrenal glands and gonads (for steroid hormones) is only tens of milligrams a day, which is easily met even at very low LDL-C.34
  • One model cited suggests the body needs only about 50-90 mg/dL of total blood cholesterol to keep its transport system functioning, against a US average near 200.3
Only a sliver of the body's cholesterol is in the bloodApproximate grams of cholesterol in the whole body versus in the bloodstream, from the physiology breakdown Louis highlighted
Whole body120–150 g
In the blood3–7 g
The rest sits inside cells, mostly in membranes; the brain holds about 25% of the total and makes its own. Source: 34
Show data
Value
Whole body120–150 g
In the blood3–7 g

Louis also describes most of the cholesterol on a blood test as "along for the ride" as a structural component of the lipoprotein particles, rather than being actively delivered to tissues.3

These claims have been tested in trials. According to Louis's summary, FOURIER (evolocumab) and ODYSSEY OUTCOMES (alirocumab) lowered LDL-C to extremely low concentrations (below 15-20 mg/dL) without impairing adrenal steroid production, gonadal hormone production or vitamin D levels.4 A 2025 review that Gokhan summarized likewise concludes that concerns about hormone disruption are unsupported by large-scale data.6

A nine-minute Nutrition Made Simple video the group shared tackles these myths together.2 As one post puts it, the problem is not cholesterol itself but having too many ApoB-containing particles in the bloodstream; at high levels they get trapped in artery walls and drive plaque.18

Myth 3: "LDL is only a marker, and the research is flawed"

The evidence for causation

The group presents the case for LDL as causal as coming from several independent directions that agree.

  • History. Louis shared a slide from Tom Dayspring on Nikolai Anitschkov's 1913 experiment, in which feeding pure cholesterol (not meat or protein-linked cholesterol, per Dayspring) produced foam cells and plaque. Louis notes this is historical context rather than trial data.20
  • Genetics. A chart from a European Atherosclerosis Society consensus statement shows that variants that affect LDL through different pathways (LDLR, PCSK9, APOB, HMGCR, NPC1L1, SORT1, ABCG5/8) change coronary risk in proportion to the LDL change, the same linear relationship seen in statin trials.8 Lifetime relative risk reductions on that chart range from about 5% to 90%. Louis converts one of them into absolute terms: with an average lifetime heart attack risk of about 20%, a 90% reduction from a PCSK9 variant leaves about 2%.8
  • A log-linear pattern. A quoted post argues the relationship is log-linear and consistent whatever the mechanism, with roughly 50-55% lower cardiovascular risk per 1 mmol/L of lifelong LDL reduction across genetics, statins, PCSK9 inhibitors and ezetimibe.21 Another analysis puts a lifelong genetic reduction of about 39 mg/dL at roughly 55% lower coronary heart disease risk, about three times the per-unit benefit seen in statin trials started in middle age. It also cites PCSK9 loss-of-function carriers with 15-28% lower LDL and 47-88% lower CHD risk.22
  • Drugs and diet. Gokhan's long article notes that the FDA has approved about 16 LDL-lowering drugs, that nearly every method of lowering LDL reduces cardiovascular events, and that diet changes such as cutting saturated fat also lower LDL.23
  • Review-level support. A 2026 NEJM review on the inherited basis of coronary artery disease, as shared by Louis, says LDL and ApoB are causal risk factors, supported by human genetics, Mendelian randomization and randomized trials.9 A 2024 Mendelian randomization study (Martin et al.) summarized by Gokhan found that genetically higher ApoB shortened healthspan, with an effect independent of LDL.24

Exposure over time

The "plaque-years" idea explains why the same LDL number can mean different things at different ages. The group's posts describe risk as depending on both how high LDL is and for how long.

  • Gokhan estimates that a 70 mg/dL lowering sustained for 30 years gives about 60% lifetime risk reduction (a figure he read from a chart), and notes that effects beyond roughly 80 mg/dL of lowering are not well known.25
  • A meta-analysis cited by Gokhan found the relative reduction in major vascular events per mmol/L lowered grows with treatment duration: 12% at year 1, 20% at year 3, 23% at year 5 and 29% at year 7.16
  • In a cross-sectional study of more than 8,000 people not on lipid drugs, endothelial dysfunction appeared above about 4,000 mg-years/dL of cumulative exposure (age x LDL-C), smooth muscle dysfunction above 5,000, and carotid wall thickening and plaque from 6,000.26
  • In the Framingham Offspring cohort, 11-20 years of hyperlipidemia by age 55 meant a 16.5% future CHD risk, versus 4.4% for those with none.22
  • A 2020 Circulation modeling study found that starting lipid lowering at 40-49 could cut projected 30-year risk from 17% to 6-12%, whereas waiting 10-20 years left 13-15%. It did not quantify the harms of statin-related diabetes risk.27
The diagram from the cumulative-exposure study: an artery moves from intact to endothelial dysfunction, smooth muscle dysfunction and plaque as cumulative LDL-C exposure passes about 4,000, 5,000 and 6,000 mg-years/dL.
The diagram from the cumulative-exposure study: an artery moves from intact to endothelial dysfunction, smooth muscle dysfunction and plaque as cumulative LDL-C exposure passes about 4,000, 5,000 and 6,000 mg-years/dL.26
More years of high cholesterol, more future heart diseaseFuture coronary heart disease risk by years of hyperlipidemia by age 55, Framingham Offspring cohort
No early hyperlipidemia4.4%
11–20 years of hyperlipidemia16.5%
Observational cohort data. Source: 22
Show data
Value
No early hyperlipidemia4.4%
11–20 years of hyperlipidemia16.5%
Starting lipid lowering in your 40s left the least riskProjected 30-year cardiovascular risk in people with high cholesterol, 2020 Circulation modeling study (ranges span the models used)
No treatment17%
Waiting 10–20 years to start13–15%
Starting at age 40–496–12%
A modeling study, not a trial; it did not quantify the harms of statin-related diabetes risk. Source: 27
Show data
Value
No treatment17%
Waiting 10–20 years to start13–15%
Starting at age 40–496–12%

Gokhan's takeaway, shared in several posts, is "lower LDL-C, earlier, longer".2528

The "speed" analogy

Louis uses a driving analogy. Drivers at 50 mph crash less often than drivers at 100 mph, yet many 50 mph drivers still crash. That does not make speed non-causal; lowering it simply lowers risk and does not give blanket protection, and other factors must also be addressed. LDL works the same way.29

Myth 4: "Very low LDL is dangerous"

This is where the posts show the most nuance, and where they partly disagree.

The reassuring evidence. A 2025 review summarized by Gokhan argues the benefits of aggressive LDL lowering outweigh mostly theoretical risks. It reports that PCSK9 inhibitors add a 59-62% LDL-C reduction on top of statins, FOURIER showed 15% fewer primary endpoints at a median LDL-C of 30 mg/dL, and a major meta-analysis found a 21% relative risk reduction per 38.7 mg/dL (1 mmol/L) with benefit down to 21 mg/dL. It cites a hemorrhagic stroke number needed to harm of 3,333 and says the EBBINGHAUS study refuted cognitive concerns. It adds that fewer than one in four high-risk patients reach under 55 mg/dL.6

In FOURIER and its extension, among more than 5,200 people with prior ischemic stroke, those with LDL-C below 40 mg/dL versus 70 or higher had about 31% fewer major cardiovascular events and 27% fewer recurrent strokes, with no increase in hemorrhagic stroke even below 20 mg/dL.30 After an acute coronary syndrome, a European Heart Journal viewpoint Gokhan shared concludes that benefit continues down to around 30 mg/dL.31

The cautionary view. Louis argues that forcing LDL-C below 20 in low-risk people with multiple drugs is unwise. He quotes Harvard's Walter Willett saying very low LDL appears to raise the risk of hemorrhagic stroke, citing Japanese experience and Mendelian randomization of the gene regulated by statins. Louis stresses that this does not apply to high-risk people, for whom the benefit on heart attack and ischemic stroke outweighs the possible hemorrhagic stroke risk, and that "your LDL target should scale with your level of risk".32

The two views are reconciled by risk-scaling rather than by one side winning. The NEJM review shared by Louis calls the clinical message "proportionality, not lower for everyone": focus on absolute risk, identify who gains meaningfully from drugs, and avoid unnecessary treatment in truly low-risk people with tailored lifestyle changes instead.9

The group's guideline posts show how targets scale. A 2023 JAHA review gives at least 50% reduction and below 70 mg/dL for high risk, and below 55 mg/dL (or below 40 mg/dL after recurrent events on statins) for very high risk.33 The ESC/EAS summary posted by Louis lists below 55 mg/dL for very high risk, below 70 for high, below 100 for moderate and below 116 for low risk (consider).34

Risk tierESC/EAS summary342023 JAHA review33
Very highBelow 55 mg/dLBelow 55 mg/dL, or below 40 mg/dL after recurrent events on statins
HighBelow 70 mg/dLAt least 50% reduction and below 70 mg/dL
ModerateBelow 100 mg/dLNot covered in the post
LowBelow 116 mg/dL (consider)Not covered in the post

Other claims that travel with cholesterol denial

"LDL is necessary but not sufficient, so it can't be the cause"

Louis summarizes a Joel Kahn video: there are at least 25 major risk factors, all worth addressing, but LDL is special because it appears necessary for atherosclerosis, while it is not always sufficient, since some people with very high LDL never form plaque. No other risk factor has been shown to be necessary, which is why cardiologists focus on it.35 There is also a lesson in the other direction: Louis notes that a zero CAC score does not rule out blockages, since 54% of 23,759 symptomatic patients in the Western Denmark Heart Registry had CAC zero and soft plaque can precede calcification by years.36

"Particle size, HDL and ratios tell the real story"

Louis's fact-check of keto and carnivore influencers separates truth from error. ApoB is indeed the best lipid marker, and LDL-C usually tracks ApoB, though discordance happens. Particle size does not matter once particle number is counted. Most saturated fats raise LDL-P, ApoB and LDL-C, and studies finding saturated fat harmless used a standard Western diet as the comparison. HDL is a crude proxy for insulin resistance and metabolic syndrome rather than a direct protector, and he cites Keto-CTA, in which people with very high LDL on keto showed soft plaque progression 3.8x faster than comparison participants.37

On HDL, five large trials of HDL-raising drugs (AIM-HIGH, HPS2-THRIVE, dal-OUTCOMES, ILLUMINATE, ACCELERATE) failed to reduce events, and in one (ILLUMINATE) cardiovascular death increased. Louis adds that some HDL subfractions might still prove protective.38

ApoB is also relevant to a subtle point: in 13,015 statin users from the Copenhagen General Population Study, those with high ApoB but normal LDL-C had a 49% higher heart attack rate and 21% higher all-cause mortality, while high LDL-C with normal ApoB showed no excess risk.39 Louis shared an explainer video on ApoB and discordance.40

The infographic Louis shared on the Copenhagen General Population Study (13,015 adults on statins, 8-year follow-up): when ApoB and LDL-C disagreed, high ApoB came with 49% more heart attacks and 21% more deaths, while high LDL-C with normal ApoB carried no added risk.
The infographic Louis shared on the Copenhagen General Population Study (13,015 adults on statins, 8-year follow-up): when ApoB and LDL-C disagreed, high ApoB came with 49% more heart attacks and 21% more deaths, while high LDL-C with normal ApoB carried no added risk.39

"Seed oils and 'sugar, not fat' are the real culprits"

The group links cholesterol denial to a wider ecosystem of nutrition claims. On seed oils, Louis cites a New York Times article reporting that higher omega-6 intake or blood levels are associated with lower risk of cardiovascular disease, type 2 diabetes, cancer and earlier death41, a 2019 pooled analysis of 30 prospective cohorts linking higher blood linoleic acid to lower heart disease and diabetes risk42, and his claim that dozens of randomized trials show omega-6 oils do not raise inflammation.43 Stanford's Christopher Gardner is quoted as saying seed oils are preferable to saturated fat44, and Harvard's Nutrition Source credits the PREDIMED trial with showing fewer major cardiovascular events (over 4.8 years) with a Mediterranean diet plus olive oil or nuts.45

Gokhan offers an account of why such claims feel convincing: people who improve on low-carbohydrate diets lose trust in guidelines, and nutrition epidemiology can be skewed by reverse causation and socioeconomic confounding, which only intervention trials resolve.46 This is an argument about the limits of observational diet studies, not about LDL itself, and it is one-sided.

What this means for you

The group's admins are not clinicians, and these points are discussion summaries rather than medical advice. They suggest the following to discuss with your own doctor.

  • Treat the link between low cholesterol and mortality in observational data with suspicion, since illness lowers cholesterol.1012
  • Do not rely on a single reading in isolation. Duration of exposure matters, and the group's admins favor lowering LDL early and sustaining it.2228
  • Ask about ApoB as well as LDL-C if results seem discordant.3739
  • Match LDL goals to your absolute risk, using guideline tiers as a reference point.93334
  • If you are at high risk, Louis's "Rule #1" is to find a good cardiologist and listen to them, and, if you want to add natural or alternative approaches, to do so in addition to treatment rather than instead of it. He notes that social-media videos often cherry-pick one study out of a hundred.47
  • Be careful with anecdotes. Louis points to a carnivore dieter who avoided medication, with a family history and high LDL-C, and developed heart disease.48

Frequently asked questions

If low LDL is safe, why do some very old people with low cholesterol die sooner?

Because illness lowers cholesterol before death, so low values in the elderly often mark disease already underway. People with lifelong genetically low LDL do not show shorter lives or more cancer.15

Do statins and LDL-lowering drugs cause diabetes?

Genetically low LDL and statins both raise type 2 diabetes risk a little, according to the post Louis quoted. That risk is concentrated in people already near the metabolic edge, such as those with impaired fasting glucose, a large waist or high triglycerides; those with none of these showed essentially no added diabetes in big trials.1

Can plaque be reversed or halted?

Gokhan's article argues that high-dose statins, alone or with ezetimibe or PCSK9 inhibitors, can slow and possibly halt plaque progression.23 He also describes one person, Charles Grashow, who regressed his CAC score with high-dose statin, ezetimibe, nattokinase and lifestyle. That is a single anecdote.25

Does a perfect metabolic profile mean LDL no longer matters?

Not according to the group. Louis commented on a publicly released health memo in which LDL was 53 mg/dL on rosuvastatin and ezetimibe despite fasting glucose 83, A1C 5.3% and TG/HDL of 104/70, and used it to illustrate that LDL treatment can be appropriate despite good metabolic markers.49

Does "LDL is causal" mean lower is always better for everyone?

No. Benefit has been shown down to very low levels in high-risk patients, but Louis and the NEJM review he shared argue the target should scale with absolute risk.6932

The evidence behind this summary38 studies · 1 meta-analysis · 9 trials · 6 MR · 7 observational

The 49 group posts cited above discuss 38 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Meta-analyses 1Randomized trials 9Mendelian randomization 6Observational studies 7Reviews & guidelines 10Animal & lab studies 1Other sources 4

Strongest evidence discussed

All 38 studies and sources
Sources from the group (49)
  1. Why high cholesterol 'protects' in observational data: reverse causation, not low-LDL harm Louis Nervegna · Sep 06, 2026 · Facebook
  2. Video debunks four myths about cholesterol in nine minutes Gokhan Can · Nov 18, 2024 · Facebook
  3. Blood carries only 2-5% of body cholesterol; cells and the brain make their own Louis Nervegna · May 30, 2026 · Facebook
  4. Tissues make their own cholesterol: even very low LDL-C does not impair hormone production Louis Nervegna · Sep 17, 2026 · Facebook
  5. Low LDL's link to cancer is reverse causality: cancer lowers cholesterol, not vice versa Louis Nervegna · Dec 21, 2023 · Facebook
  6. Review: aggressive LDL lowering outweighs theoretical risks, yet few reach <55 mg/dL Gokhan Can · Oct 28, 2025 · Facebook
  7. 200+ studies and 2 million participants show LDL drives atherosclerosis dose-dependently Louis Nervegna · Oct 28, 2026 · Facebook
  8. Mendelian randomization: lifelong lower LDL tracks linearly with lower heart disease risk Louis Nervegna · Oct 10, 2026 · Facebook
  9. NEJM review: LDL targets should scale with absolute risk, not 'lower for everyone' Louis Nervegna · Feb 05, 2026 · Facebook
  10. Wikipedia cites 'low cholesterol causes mortality' as a correlation-causation fallacy Louis Nervegna · Dec 05, 2024 · Facebook
  11. Why low LDL-C correlates with higher mortality: causation versus correlation Gokhan Can · Nov 17, 2023 · Facebook
  12. U-shaped mortality curves for cholesterol, BMI, A1C and BP reflect reverse causality Louis Nervegna · Jun 12, 2024 · Facebook
  13. Video: cholesterol and risk of death, new evidence Gokhan Can · Nov 17, 2023 · Facebook
  14. Video: why lowering LDL does not increase mortality Gokhan Can · Nov 19, 2023 · Facebook
  15. Lowering LDL does not increase mortality; the U-shaped curve is a misinterpretation Louis Nervegna · Feb 26, 2026 · Facebook
  16. Lifelong lower LDL adds about 1.2 years of life per SD, and benefits compound over time Gokhan Can · Sep 27, 2025 · Facebook
  17. Mendelian randomization: BMI, BP, LDL and type 2 diabetes lower odds of longevity Gokhan Can · Jan 25, 2025 · Facebook
  18. Why elevated cholesterol harms: ApoB particles drive plaque and inflammatory aging Gokhan Can · Nov 09, 2025 · Facebook
  19. Nearly every cell makes its own cholesterol, especially brain cells Louis Nervegna · Oct 29, 2026 · Facebook
  20. Anitschkov's 1913 cholesterol-feeding experiment first showed cholesterol causes plaque Louis Nervegna · Aug 29, 2024 · Facebook
  21. Lower lifetime LDL exposure means lower CVD risk across genetic variants and drugs Louis Nervegna · Jun 01, 2026 · Facebook
  22. Lifelong cumulative LDL exposure ('cholesterol-years') drives atherosclerosis risk Gokhan Can · Sep 01, 2025 · Facebook
  23. The case for LDL lowering: statins, ezetimibe, PCSK9 inhibitors and diet all reduce events Gokhan Can · Sep 07, 2024 · Facebook
  24. Mendelian randomization: higher ApoB shortens healthspan and may raise Alzheimer's risk Gokhan Can · Feb 25, 2024 · Facebook
  25. The longer the lower the better: lifelong LDL lowering and an estimated 60% risk reduction Gokhan Can · Nov 20, 2023 · Facebook
  26. Cumulative LDL-C thresholds: endothelial damage above 4000, plaque from 6000 mg-year/dL Gokhan Can · Sep 01, 2025 · Facebook
  27. Starting lipid lowering at 40-49 could cut 30-year ASCVD risk from 17% to 6-12% Gokhan Can · Nov 20, 2023 · Facebook
  28. LDL-C is cumulative exposure: lowering it earlier and longer matters most Gokhan Can · Jul 02, 2026 · Facebook
  29. LDL works like speed in crashes: lowering it reduces risk without guaranteeing safety Louis Nervegna · May 01, 2026 · Facebook
  30. FOURIER stroke analysis: LDL below 40 mg/dL cut major events ~31% and recurrent stroke 27% Gokhan Can · Nov 13, 2025 · Facebook
  31. After acute coronary syndrome, lower LDL sooner is better, down to about 30 mg/dL Gokhan Can · Sep 23, 2025 · Facebook
  32. Louis: forcing LDL-C below 20 in low-risk people is unwise, per Willett on brain bleeds Louis Nervegna · Mar 30, 2024 · Facebook
  33. Evolving LDL-C management (JAHA 2023): risk categories, thresholds and treatment goals Gokhan Can · Nov 25, 2023 · Facebook
  34. 2025 ESC/EAS LDL targets: below 55 mg/dL for very high risk, below 70 for high risk Louis Nervegna · Nov 20, 2025 · Facebook
  35. LDL is necessary but not always sufficient for atherosclerosis, among 25+ risk factors Louis Nervegna · Mar 25, 2024 · Facebook
  36. A zero CAC score does not rule out blockages: 54% of 23,759 symptomatic patients had CAC 0 Louis Nervegna · Jan 01, 2025 · Facebook
  37. Fact-checking keto and carnivore influencer claims about LDL, ApoB and saturated fat Louis Nervegna · May 28, 2025 · Facebook
  38. Drugs that raise HDL have repeatedly failed to cut cardiovascular events Louis Nervegna · Jun 12, 2026 · Facebook
  39. On statins, high ApoB with normal LDL-C raised MI risk 49%; high LDL-C alone did not Louis Nervegna · Jul 30, 2026 · Facebook
  40. Video: why ApoB is a better CVD risk marker than LDL-C and what discordance means Louis Nervegna · Mar 09, 2024 · Facebook
  41. NY Times: higher omega-6 linked to lower CVD, diabetes, cancer and mortality Louis Nervegna · Nov 24, 2024 · Facebook
  42. Medical schools push back on seed-oil myths; pooled cohorts link omega-6 to lower risk Louis Nervegna · Jun 18, 2025 · Facebook
  43. Dozens of human RCTs show omega-6 oils from nuts and seeds do not cause inflammation Louis Nervegna · Sep 10, 2024 · Facebook
  44. Stanford's Gardner: seed oils beat saturated fat and inflammation fears are myths Louis Nervegna · Sep 15, 2025 · Facebook
  45. Harvard: unsaturated fats protect, trans fats harm; PREDIMED backs olive oil and nuts Louis Nervegna · Sep 10, 2025 · Facebook
  46. Why diet-health epidemiology may mislead: reverse causation and socioeconomic confounding Gokhan Can · Jan 15, 2025 · Facebook
  47. At high risk of a heart attack? Find a good cardiologist and add, don't replace, treatment Louis Nervegna · Feb 26, 2024 · Facebook
  48. A carnivore dieter's heart problems highlight the risk of social-media advice Louis Nervegna · Nov 07, 2025 · Facebook
  49. Latest presidential health report shows LDL of 53 mg/dL on rosuvastatin plus ezetimibe Louis Nervegna · May 30, 2026 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary